Experimental Hematology
Volume 38, Issue 6 , Pages 472-480 , June 2010

Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway

  • Min Lu

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • ,
  • Wei Zhang

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • ,
  • Yan Li

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • ,
  • Dmitriy Berenzon

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • ,
  • Xiaoli Wang

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • ,
  • Jiapeng Wang

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • ,
  • John Mascarenhas

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • Myeloproliferative Disorder Research Consortium, New York, NY., USA
    • ,
  • Mingjiang Xu

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • Myeloproliferative Disorder Research Consortium, New York, NY., USA
    • ,
  • Ronald Hoffman

      Affiliations

    • Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY., USA
    • Myeloproliferative Disorder Research Consortium, New York, NY., USA
    • Corresponding Author InformationOffprint requests to: Ronald Hoffman, M.D., Division of Hematology/Oncology, Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029

Received 25 February 2010 ,Revised 8 March 2010 ,Accepted 9 March 2010.

References 

  1. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148
  2. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106:3374–3376
  3. Levine RL, Gilliland DG. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol. 2007;14:43–47
  4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  5. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005;11:546–554
  6. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107:451–458
  7. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998;83:1205–1213
  8. Liu E, Jelinek J, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101:3294–3301
  9. Massaro P, Foa P, Pomati M, et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol. 1997;56:126–128
  10. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86:402–404
  11. Chott A, Gisslinger H, Thiele J, et al. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol. 1990;74:10–16
  12. Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet. 1988;2:960–961
  13. Giles FJ, Singer CR, Gray AG, et al. Alpha-interferon therapy for essential thrombocythaemia. Lancet. 1988;2:70–72
  14. Sacchi S, Leoni P, Liberati M, et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol. 1994;68:247–250
  15. Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003;98:100–109
  16. Lengfelder E, Berger U, Hehlmann R. Interferon alfa in the treatment of polycythemia vera. Ann Hematol. 2000;79:103–109
  17. Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev. 2007;59:1222–1241
  18. Grace MJ, Cutler DL, Bordens RW. Pegylated IFNs for chronic hepatitis C: an update. Expert Opin Drug Deliv. 2005;2:219–226
  19. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51:81–86
  20. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037–2040
  21. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–3072
  22. Samuelsson J, Hasselbalch H, Bruserud O, et al. Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397–2405
  23. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110:2012–2018
  24. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther. 2003;98:129–142
  25. Goh KC, Haque SJ, Williams BR. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 1999;18:5601–5608
  26. Uddin S, Lekmine F, Sharma N, Majchrzak B, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem. 2000;275:27634–27640
  27. Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem. 2001;276:28570–28577
  28. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–1097
  29. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108:3128–3134
  30. Ishii T, Xu M, Zhao Y, Hu WY, Ciurea S, Bruno E, et al. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera. Leukemia. 2007;21:373–374
  31. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem. 2007;282:20047–20051
  32. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem. 1987;56:727–777
  33. Biron CA. Role of early cytokines, including α and β interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin Immunol. 1998;10:383–390
  34. Carlo-Stella C, Cazzola M, Gasner A, et al. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood. 1987;70:1014–1019
  35. Castello G, Lerza R, Cerruti A, et al. The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol. 1994;87:621–623
  36. Wang Q, Miyakawa Y, Fox N, Kaushansky K, et al. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96:2093–2099
  37. Sato T, Yoshihara NOH, Suda FAT, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion. Nat Med. 2009;15:696–700
  38. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904–908
  39. Grace MJ, Lee S, Bradshaw S, et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem. 2005;280:6327–6236
  40. Larsen TS, Bjerrum OW, Pallisgaard N, et al. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol. 2008;87:847–850
  41. Brassard D, Bradshaw S, Chapman J, et al. Differential responsiveness of interferon α 2 signaling by pagylated interferon α 2b and pagylated interferon a 2a. Hepatology. 2002;36:548A
  42. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006;107:3339–3341
  43. Cox S, Youngster S, Leaman D, et al. Pegylated interferon α 2b and pegylated interferon α 2a. Hepatology exhibit different anti-viral activity in vitro. Hepatology. 2002;36:547A
  44. Leaman D, Brassard D, Cox S, et al. Pagylated interferon α 2b and pagylated interferon α 2a. Hepatology exhibit different anti-proliferative activity in vitro. Hepatology. 2002;36:547A
  45. Samuelsson J, Mutschler M, Birgegård G, et al. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2006;91:1281–1282
  46. Xiong Z, Liu E, Yan Y, Silver RT, et al. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol. 2006;177:4907–4916
  47. Xiong Z, Yan Y, Liu E, et al. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol. 2007;122:279–287
  48. Milhem M, Mahmud N, Lavelle D, et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood. 2004;103:4102–4110
  49. Alsayed Y, Uddin S, Mahmud N, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem. 2001;276:4012–4019

PII: S0301-472X(10)00082-2

doi: 10.1016/j.exphem.2010.03.005

Experimental Hematology
Volume 38, Issue 6 , Pages 472-480 , June 2010

Article Tools

* Image Usage & Resolution